St. Jude Medical (NYSE: STJ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : St. Jude Medical (NYSE: STJ)

STJ 80.82

0.0%

Jan 18 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harbor who wrote (20)	12/29/1997 10:06:00 AM
From: Dan Hughes	Read Replies (1) of 33

Tissue valves have been around for along time, primarily marketed by Baxter Edwards. Medtronic received approval for one of there own and it is my opinion, based on some scuttlebut that St. Jude will also be coming out with one soon. Basically, tissue valves are used in the older patients were the life span of the valve isn't an issue. A mechanical valve, is used in a younger patient, who must then take blood thinners the rest of their lives. The plus is that they probably will not have to have it replaced. The real threat to St. Jude probably lies in the mechanical valves that baxter has the distribution rights for. These are manufactured by Sorin Biomedica in Italy and are presently not approved in the US. I don't really know the timeframes for the approval process on Baxters end. I was interested in St. Jude future from other investors perspectives because I wasn't sure if the company was going to be acquiring other companies in the near future. Dan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next